Sepsis syndrome in urology

BY CHRISTIAN NAYAR, ANIKET DESHPANDE AND RICHARD PORTER

T
here are approximately 100,000 cases of sepsis per year in the UK, of which 37,000 result in death (this is more than prostate cancer, breast cancer, HIV / AIDS and road traffic accidents combined). Urosepsis is defined as sepsis caused by a urinary tract infection (UTI). Approximately 20-30% of cases of sepsis are due to urosepsis. The systemic inflammatory response syndrome (SIRS) is recognised as the first event in this septic cascade that if not halted ends in multi-organ failure and death.

The treatment of urosepsis depends upon a) prompt recognition of the condition, b) appropriate and rapid initiation of antimicrobial therapy, and c) combination of adequate life-supporting care, adjunctive measures as appropriate. The drainage of any obstruction in the urinary tract is also essential as a first-line treatment. The management of these patients should be with a multidisciplinary approach between urologists, intensive care doctors and microbiologists.

An admission with severe sepsis places a patient at a level of risk of mortality approximately 6-10 fold greater than with an acute myocardial infarction and 4-5 times greater than an acute stroke. In 2002, critical care experts agreed that definitive action was required to reduce the mortality from severe sepsis. The Surviving Sepsis Campaign (SSC) was developed as a collaboration between the European Society of Critical Care Medicine, the International Sepsis Forum and the Society of Critical Care Medicine.

A desire to reduce the mortality of sepsis by 25% over five years became known as the Barcelona declaration. Guidelines were first published in 2004 and then re-drafted in 2008 and again in 2012 for the management of severe sepsis and septic shock. These became known as the sepsis six.

UTI can manifest as a spectrum from bacteriuria with limited clinical symptoms to sepsis or severe sepsis depending on localised or systemic extension (Table 1). Severe sepsis has a mortality rate of 20-42% [1]. In recent years, whilst the incidence of sepsis has increased by 8.7% per year the associated mortality has decreased (from 27.8% to 17.9% from 1995 to 2000) suggesting improved management of these patients.

In urosepsis, as with other types of sepsis, the severity is dependent upon the host response. Patients that are more likely to develop urosepsis include: elderly patients, diabetics and the immunosuppressed e.g. patients on chemotherapy or steroids, HIV patients or transplant recipients. Urosepsis may also depend upon local factors in the urinary tract such as urolithiasis, obstruction of the urinary tract at any level, uropathy, neurogenic bladder disorders or instrumentation of the urinary tract.

Common pathogens

The predominant pathogens identified on urine culture in patients with urosepsis are enterobacteria, with Escherichia coli being the most common microorganism. Pseudomonas aeruginosa and Serratia sp. are likely to be multiresistant and difficult to treat. Risk factors

<table>
<thead>
<tr>
<th>Table 1: Spectrum of UTI.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disorder</td>
</tr>
<tr>
<td>Infection</td>
</tr>
<tr>
<td>Bacteriuria</td>
</tr>
<tr>
<td>Bacteraemia</td>
</tr>
</tbody>
</table>
| Systemic inflammatory response syndrome (SIRS) | Response to a wide variety of clinical insults, which can be infectious as in sepsis but may be non-infectious in aetiology (for example: burns or pancreatitis). This systemic response is manifest by two or more of the following conditions:  
  • Temperature >38 or <36 degrees Celsius.  
  • Heart rate >90 bpm.  
  • Respiratory rate >20 breaths per minute or PaCO₂ <32mmHg (<4.3kPa).  
  • WBC >12,000 cells/mm³ or <4,000 cells/mm³ or >10% immature (band) forms. |
| Sepsis                  | Activation of the inflammatory process due to infection.                    |
| Hypotension             | Systolic blood pressure <90mmHg or a reduction of >40mmHg from baseline in the absence of other causes of hypotension. |
| Severe sepsis           | Sepsis associated with organ dysfunction, hypoperfusion or hypotension. Hypoperfusion and perfusion abnormalities may include but are not limited to lactic acidosis, oliguria, or acute alteration of mental state. |
| Septic shock            | Sepsis with hypotension despite adequate fluid resuscitation along with the presence of perfusion abnormalities that may include, but are not limited to lactic acidosis, oliguria, or acute alteration in mental status. Patients who are on inotropic or vasopressor agents may not be hypotensive at the time that perfusion abnormalities are measured. |
| Refractory septic shock | Septic shock that lasts for > one hour and does not respond to fluid administration or pharmacological intervention. |
for bacteraemia are complicated UTIs, such as pyelonephritis or obstructive uropathy. Elderly and immunocompromised patients are at a higher risk of experiencing severe complications of genitourinary infections, for instance renal abscesses or xanthogranulomatous pyelonephritis.

Pathophysiology
The major pathogenesis of sepsis is due to the presence of endotoxins released into the circulation by gram negative bacteria. This in turn results in a cascade of events resulting in a release of mediators such as tumour necrosis factor alpha, Interleukins 2, 6 and 8 from target cells (for example macrophages, neutrophils, lymphocytes and plasma cells), and activation of the kinin system, complement system and fibrinolytic system. These events result in widespread microvascular injury, tissue ischaemia and the clinical manifestations of sepsis.

Treatment
The optimal approach to treating patients with urosepsis involves three goals: a) early recognition, b) causal treatment / source control (relief of urinary tract obstruction) and c) timely administration of antimicrobial agents.

Early recognition
Physical examination with assessment of the vital signs (respiratory rate, oxygen saturation, temperature, blood pressure, pulse rate and urine output) are mandatory. There are several ‘early warning scores’ such as the Medical Early Warning Score (MEWS) and the National Early Warning Score (NEWS): these are simple physiological scores designed to allow early detection of deterioration of a patient’s physiological parameters.

Sepsis six – survive sepsis
- Administer high flow oxygen.
- Take blood cultures.
- Give broad spectrum antibiotics.
- Give IV fluid challenges.
- Monitor serum lactate and haemoglobin (this can be done via blood gas analysis).
- Accurately measure hourly urine output.

Proper care delivered within the first hour can potentially double a patient’s chances of survival.

Oxygen therapy
Aim to give high concentration oxygen to septic patients initially via an oxygen mask with reservoir bag. After initial resuscitation aim for an oxygen saturation target of >94%. It should be remembered that septic patients are exempt from the British Thoracic Society guidelines – this still may be appropriate even in chronic obstructive pulmonary disease, however these patients need to be closely monitored.

Blood cultures
The microbiological diagnosis is based on blood cultures. If the patient has a CVP line blood cultures can be sent off centrally (from the CVP or Hickman line) as well as peripherally. Sputum, urine and pus are also sent for microbiological analysis.

Antimicrobial therapy
Empirical initial treatment should be with broad spectrum intravenous antibiotics, including, if appropriate, anti-fungal cover, which should be adapted once specific cultures and sensitivities become available. The dosage of antibiotic is obviously vital and in general should be high except in those patients with renal dysfunction.

Early administration of antibiotics within one hour of diagnosis should be mandatory. Each hour’s delay in administration has been shown to increase the risk of death by 8% [3].

Fluid resuscitation
The initial phases of sepsis combine absolute hypovolaemia (due to fluid loss into the interstitial compartment and reduced fluid intake combined with increased insensible losses through perspiration and respiration)

Table 2: Surviving sepsis campaign (SSC) bundles.

<table>
<thead>
<tr>
<th>To be completed within three hours</th>
<th>To be completed within six hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measure lactate level.</td>
<td>Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation) to maintain a mean arterial pressure MAP ≥65 mmHg.</td>
</tr>
<tr>
<td>Obtain blood cultures prior to giving antibiotics.</td>
<td>In the event of persistent arterial hypotension despite volume resuscitation (septic shock) or initial lactate ≥4 mmol/L: measure central venous pressure (CVP) and central venous oxygen saturation (ScvO2).</td>
</tr>
<tr>
<td>Administer broad spectrum antibiotics.</td>
<td>Remeasure lactate if initial lactate was elevated.</td>
</tr>
<tr>
<td>Administer 30ml/kg crystalloid for hypotension or lactate ≥4 mmol/L.</td>
<td></td>
</tr>
</tbody>
</table>

* Targets for quantitative resuscitation are CVP of ≥8 mmHg, ScvO2 of ≥70% and normalisation of lactate.
with relative hypovolaemia due to vasodilatation. This is further compounded by ventricular dysfunction, microcirculatory disorders and hypercoagulability. Organ hypoperfusion may ensue leading to shock.

Treating hypovolaemia is thus central to the management of sepsis. It is important to distinguish between initial fluid resuscitation and aggressive goal directed fluid resuscitation. The SSC recommendation is for initial boluses to a volume of 20-60ml/kg body weight prior to the consideration of invasive therapy and goal-directed therapy. Initial fluid resuscitation should be delivered in fluid challenge boluses of 250-500ml of crystalloid or 250ml of colloid over <30 minutes with clinical assessment of the response to guide the requirements for further fluid boluses until the target volume is achieved.

Initial fluid resuscitation: which fluid?
With crystalloids, a greater volume will be required to achieve the same degree of volume expansion and more oedema will develop as a result. Colloid solutions are more expensive, but give a greater and prolonged volume expansion with less volume infused. The current evidence has failed to provide any objective proof to support the use of one intravenous fluid over another. The saline versus albumin fluid evaluation (SAFE) study failed to demonstrate benefit or harm with the use of albumin compared with crystalloid.

Serum lactate
Studies have shown that lactate levels have a prognostic value and may be helpful in risk stratification of patients according to lactate levels at presentation [4]. Patients with a lactate of <4mmol/L had a mortality of <40%, compared with fewer than 15% for patients with a lactate of <2mmol/L. Other studies have shown that lactate levels can be predictive of critical care admission.

Source control
It is recommended that a specific anatomical diagnosis of infection requiring emergent source control, for example necrotising soft tissue infection in Fournier’s gangrene, pyonephrosis, peritonitis) be sought and diagnosed or excluded as soon as possible, and intervention be undertaken for source control within the first 12 hours of the diagnosis being made if feasible. Drainage of any obstruction in the urinary tract and removal of foreign bodies e.g. stones (when appropriate) should aid resolution of symptoms and recovery. It is also suggested that when source control in a severely septic patient is required the effective intervention associated with the least physiological insult should be used.

Levels of therapy
There are three levels of therapy outlined in Table 3

<table>
<thead>
<tr>
<th>Table 3: Levels of therapy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Causal therapies</td>
</tr>
<tr>
<td>1. Antimicrobial therapy</td>
</tr>
<tr>
<td>2. Source control</td>
</tr>
<tr>
<td>Supportive therapies</td>
</tr>
<tr>
<td>1. Haemodynamic stabilisation</td>
</tr>
<tr>
<td>2. Airway / respiratory</td>
</tr>
<tr>
<td>Adjunctive therapies</td>
</tr>
<tr>
<td>1. Glucocorticosteroids (controversial)</td>
</tr>
<tr>
<td>2. Avoidance of hyperglycaemia</td>
</tr>
</tbody>
</table>

“...the management of fluid and electrolyte balance is of critical importance in the care of the septic patient, particularly after the development of shock.”
Conclusion
Sepsis syndrome in urology is a serious problem with a mortality rate of between 20-40%. The Surviving Sepsis Campaign aims to reduce mortality by 25% within the next few years [8]. Prompt recognition of the symptoms may reduce the mortality by timely treatment of urinary tract disorders. Early involvement of critical care and appropriate antibiotic therapy provide the best conditions for improving patient survival. The prevention of urosepsis also involves the rationale of good infection control measures to prevent nosocomial infections and the appropriate use of antibiotic prophylaxis and antibiotic therapy.

<table>
<thead>
<tr>
<th>Table 4: Early goal directed therapy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central venous pressure (CVP)</td>
</tr>
<tr>
<td>Mean arterial pressure (MAP)</td>
</tr>
<tr>
<td>Central venous oxygen (CVO2)</td>
</tr>
<tr>
<td>Haemotcrit</td>
</tr>
<tr>
<td>Urine output</td>
</tr>
</tbody>
</table>

References

TAKE HOME MESSAGE
- ~20-30% of sepsis cases are due to urosepsis which carries a mortality rate of 20-40%.
- Prompt recognition, rapid initiation of appropriate antibiotic therapy and combination of adequate life-supporting care and adjunctive measures are vital to improving outcomes including survival.
- E. coli is the commonest pathogen in these patients, with the endotoxins released triggering a cascade of response involving TNF-α, ILs, kinins, complement pathway and fibrinolytic system, which results in the clinical manifestation of the sepsis syndrome.
- The authors recommend using an early warning scoring system e.g. NEWS to allow earlier detection of deterioration of patients' condition prompting immediate interventions.
- Early involvement and close liaison with critical care unit is imperative as these patients are quite unwell, often requiring specialist adjunctive measures e.g. vasoressors, airway support, etc. which are only provided on the unit.
- Early review of nutrition and continuing DVT prophylaxis, unless contraindicated, help towards achieving improved outcomes.

Declaration of competing interests:
None declared.

Mr Christian Nayar,
Post CCT Fellow in Female and Functional Urology, Bristol Urological Institute, UK.
E: christiannayar@doctors.org.uk

Declaration of competing interests:
None declared.

Mr Aniket Deshpande,
Post CCT Fellow in Uro-Oncology, Colchester, UK.

Declaration of competing interests:
None declared.

Dr Richard Porter,
Consultant in Adult Intensive Care and Extracorporeal Membrane Oxygenation, Leicester Royal Infirmary, UK.

Declaration of competing interests:
None declared.